M. GÜZEL, "The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis," 2014 Joint ACTRIMS-ECTRIMS Meeting , BOSTON, United States Of America, 2014
GÜZEL, M. 2014. The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis. 2014 Joint ACTRIMS-ECTRIMS Meeting , (BOSTON, United States Of America).
GÜZEL, M., (2014). The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis . 2014 Joint ACTRIMS-ECTRIMS Meeting, BOSTON, United States Of America
GÜZEL, Mustafa. "The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis," 2014 Joint ACTRIMS-ECTRIMS Meeting, BOSTON, United States Of America, 2014
GÜZEL, Mustafa. "The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis." 2014 Joint ACTRIMS-ECTRIMS Meeting , BOSTON, United States Of America, 2014
GÜZEL, M. (2014) . "The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis." 2014 Joint ACTRIMS-ECTRIMS Meeting , BOSTON, United States Of America.
@conferencepaper{conferencepaper, author={Mustafa GÜZEL}, title={The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis}, congress name={2014 Joint ACTRIMS-ECTRIMS Meeting}, city={BOSTON}, country={United States Of America}, year={2014}}